Time to prescribe dual instead of mono

Joon Young Choi, M.D.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Chronic obstructive pulmonary disease (COPD) is one of the most common diseases with profound morbidity and mortality \(^1\). Inhaled long-acting bronchodilators are the cornerstones of treatment; these not only control symptoms but also prevent exacerbation events and attenuate the decline in lung function \(^2\). Historically, tiotropium (TIO) was the first approved long-acting muscarinic antagonist (LAMA), and was one of the most commonly used inhalers in COPD patients, past decades \(^3\). Recent reports revealed that newly developed long-acting \(\beta_2\)-agonist (LABA)/LAMA combinations showed superior outcomes compared with monobronchodilators and inhaled corticosteroid (ICS)/LABA combination in terms of symptom control, attenuation of lung function decline and exacerbation \(^3\). Regarding these results, analyses of clinical outcomes in switching from a monobronchodilator to dual bronchodilators may give us some clues in treating COPD patients who have formerly used monobronchodilators.

Lee et al. \(^4\) performed a 12-week, randomized, parallel group trial on patients with mild to
moderate COPD who formerly used TIO. After randomization to indacaterol/glycopyrronium (IND/GLY) and TIO groups, the former group immediately changed their medication and the TIO group did not. After 12 weeks of their challenge, the clinical outcomes (including the pre-dose trough FEV1, the transition dyspnea index [TDI] focal score, the CAT total score and rescue medication use) were analyzed. The change in pre-dose trough FEV1, (the primary outcome) showed significantly superior in the IND/GLY group compared to TIO group (least square mean treatment difference $[\Delta] 50$ml; $p=0.01$). The changes in the TDI focal scores, CAT total scores, and rescue medication use did not differ between the groups but tended to be better in IND/GLY group. Safety index showed comparable between the two groups.

The Canadian real-world POWER study was similar to that of Lee et al. The trough FEV1 improved by 176mL by week 16 after switching from TIO to IND/GLY (70mL, in Lee et al.), and the mean TDI total scores and CAT scores also significantly improved. The safety profiles of the two groups were comparable. The CRYSTAL study, which was a multicenter randomized controlled study that investigate efficacy of direct switching to IND/GLY in moderate COPD patients, revealed more favorable outcomes in an IND/GLY group than in a monobronchodilator continuation group in terms of the trough FEV1 ($\Delta = 101$mL) and TDI score ($\Delta=1.26$). Moreover, recent pooled analyses of the SHINE, SPARK and ARISE trial data enrolling long-acting bronchodilator-naïve moderate-to-very severe COPD patients presented greater improvement in trough FEV1 in an IND/GLY compared to a TIO group ($\Delta=86$mL), in line with study of Lee et al.

These diverse studies of different study designs correspondingly support use of IND/GLY rather than TIO in previous TIO users and bronchodilator-naïve patients in COPD patients. However, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020
guideline recommends initial use of monobronchodilator for Group B and C, and permits such usage in Group D patients\(^{1}\). As the study of Lee et al. also includes mild COPD patients, the results may imply necessity of dual bronchodilators in their earlier course of the disease. The pharmacological effects of switching from TIO to IND/GLY in various GOLD subgroups have not been investigated; subgroup analyses may be important when choosing an optimal initial therapy.

Reference


